Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,489 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07629375 | Standardization of a Platform of Preclinical Models Derived From NSCLC Patients | recruiting | — | 5 | Regina Elena Cancer InstituteOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05243797 | Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation(MajesTEC-4) | recruiting | Phase 3 | 1,594 | European Myeloma Network B.V.NETWORK |
| 25 |
| Jun 4, 2026 |
| clinicaltrials |
| NCT05890677 | The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema(LYMPH) | recruiting | N/A | 280 | University Hospital, Basel, SwitzerlandOTHER | 15 | Jun 4, 2026 | clinicaltrials |
| NCT04617522 | Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment | recruiting | Phase 1 | 30 | Gilead SciencesINDUSTRY | 4 | Jun 2, 2026 | clinicaltrials |
| NCT06950385 | Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis(SERENTA) | recruiting | Phase 3 | 168 | Rapamycin Holdings Inc.INDUSTRY | 7 | Jun 2, 2026 | clinicaltrials |
| NCT07276100 | Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab | recruiting | Phase 2 | 15 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07579117 | Endoscopic Video-Assisted Nipple-Sparing Mastectomy(EVA) | recruiting | N/A | 10 | European Institute of OncologyOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07617025 | Prognostic and Predictive Role of Intrinsic Molecular Subtypes in BRCA-associated Breast Cancer(PAMBRACA) | recruiting | — | 100 | Angela TossOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05718323 | Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC(RAISE) | recruiting | Phase 2 | 44 | ETOP IBCSG Partners FoundationNETWORK | 5 | May 29, 2026 | clinicaltrials |
| NCT06822855 | Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma(LH_BIO) | recruiting | — | 755 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | May 29, 2026 | clinicaltrials |
| NCT07180693 | Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors:(BREAKER) | recruiting | — | 750 | European Institute of OncologyOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT05815927 | Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer(PROLoNg) | recruiting | Phase 3 | 200 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | May 28, 2026 | clinicaltrials |
| NCT03093116 | A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements(TRIDENT-1) | recruiting | Phase 1 / Phase 2 | 500 | Turning Point Therapeutics, Inc.INDUSTRY | 19 | May 27, 2026 | clinicaltrials |
| NCT05384626 | A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | recruiting | Phase 1 / Phase 2 | 840 | Nuvalent Inc.INDUSTRY | 15 | May 27, 2026 | clinicaltrials |
| NCT06256588 | A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma(JADE) | recruiting | Phase 3 | 864 | GlaxoSmithKlineINDUSTRY | 31 | May 26, 2026 | clinicaltrials |
| NCT06486506 | Proximal Femur Reconstruction Following Resection of Primary Bone Tumors: Analysis of the Clinical and Radiographic Results(ProFemuRe) | recruiting | — | 150 | Costantino ErraniOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07237256 | Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib(NoLEEta) | recruiting | Phase 3 | 3,902 | UNICANCEROTHER | 5 | May 26, 2026 | clinicaltrials |
| NCT06551142 | A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)(PanTumor-101) | recruiting | Phase 1 | 845 | GlaxoSmithKlineINDUSTRY | 13 | May 22, 2026 | clinicaltrials |
| NCT06567782 | A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer(AZUR-4) | recruiting | Phase 2 | 120 | GlaxoSmithKlineINDUSTRY | 6 | May 22, 2026 | clinicaltrials |
| NCT06709872 | A Prospective Multicenter Diagnostic Biomarker Study to Discriminate Borderline From Stage I Invasive Ovarian Cancer(BIOC) | recruiting | — | 400 | KU LeuvenOTHER | 3 | May 22, 2026 | clinicaltrials |
| NCT07601464 | Evaluation of Tissue and Circulating microRNA Profiles in Patients With Hepatocellular Carcinoma Subjected to Thermal Ablation(TERMOMIRNA) | recruiting | — | 150 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06504147 | A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery | recruiting | Phase 2 | 114 | Oncoinvent Solutions ASINDUSTRY | 6 | May 20, 2026 | clinicaltrials |
| NCT06588478 | A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | recruiting | Phase 2 | 249 | Loxo Oncology, Inc.INDUSTRY | 18 | May 19, 2026 | clinicaltrials |
| NCT07595653 | A Study to Evaluate the Impact of Efgartigimod on Overall Disease Experience of People Suffering From Generalized Myasthenia Gravis (gMG) in Italy(POEMA) | recruiting | — | 100 | argenxINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT04421820 | BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 220 | Bold Therapeutics, Inc.INDUSTRY | 7 | May 18, 2026 | clinicaltrials |
| NCT06757634 | Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | recruiting | Phase 3 | 1,180 | Celcuity IncINDUSTRY | 22 | May 18, 2026 | clinicaltrials |
| NCT07594262 | NET-TIME: Inflammatory Tumor Microenvironment in Pituitary Neoplasm(NET-TIME) | recruiting | — | 60 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT05300464 | A Clinical Investigation to Confirm the Ability of MammoWave in Breast Lesions Detection | recruiting | N/A | 600 | Umbria Bioengineering TechnologiesINDUSTRY | 2 | May 15, 2026 | clinicaltrials |
| NCT07093801 | Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer | recruiting | — | 300 | Novartis PharmaceuticalsINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07556874 | Descriptive Analysis of Surgeries in Patients With Multiple Osteochondromas(CHIROS) | recruiting | — | 300 | Istituto Ortopedico RizzoliOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06268457 | Arterial Chemoembolization for the Treatment of Desmoid Fibromatosis(Embodesmo) | recruiting | — | 20 | Istituto Ortopedico RizzoliOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06284317 | A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.(ADOPT-lung) | recruiting | Phase 3 | 290 | ETOP IBCSG Partners FoundationNETWORK | 10 | May 14, 2026 | clinicaltrials |
| NCT06417814 | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(TROPION-Lung15) | recruiting | Phase 3 | 744 | AstraZenecaINDUSTRY | 27 | May 14, 2026 | clinicaltrials |
| NCT06934863 | Rate of Malignant Transformation and Clinical Characteristics Among an Oral Lichen Planus Cohort: a Retrospective Center Experience(LPO_CMR) | recruiting | — | 300 | Catholic University of the Sacred HeartOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07395336 | Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)(COMBINE-01) | recruiting | Phase 2 | 26 | European Institute of OncologyOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06291896 | A Clinical Investigation to Evaluate Microwave Imaging Via MammoWave® in a Population-based Screening Program for Early Breast Cancer Detection | recruiting | N/A | 10,000 | Umbria Bioengineering TechnologiesINDUSTRY | 5 | May 13, 2026 | clinicaltrials |
| NCT07203911 | Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled Trial(SURGIO) | recruiting | N/A | 150 | Tobias TodsenOTHER | 5 | May 13, 2026 | clinicaltrials |
| NCT07583485 | GIM27-THERapy: a Study to Describe the Effectiveness of Tucatinib in Combination With Capecitabine and Trastuzumab in the Treatment of Metastatic HER-2 Positive Breast Cancer Patients in Real World Setting(THERapy) | recruiting | — | 300 | Fondazione OncotechOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05492682 | START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | recruiting | Phase 1 | 15 | Valo Therapeutics OyINDUSTRY | 2 | May 12, 2026 | clinicaltrials |
| NCT05918302 | Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.(LEVEL) | recruiting | Phase 3 | 170 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 4 | May 12, 2026 | clinicaltrials |
| NCT06224283 | Radiomics Compared With Conventional Response Criteria for Predicting Progression of Desmoid Tumor After Cryoablation(Cryomics) | recruiting | — | 21 | Istituto Ortopedico RizzoliOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07283224 | Anonymization of Clinical Data From Pseudonymized Databases Collected as Part of Previus Clinical Trials on Multiple Myeloma | recruiting | — | 600 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07580196 | Bilateral Versus Unilateral Lymph Node Dissection in High-Risk Prostate Cancer (BALANCE)(BALANCE) | recruiting | N/A | 820 | University of Turin, ItalyOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07582354 | MMAPPIN' Study: Multiple Myeloma Analysis For Patient-specific Insights to Dissect Disease Heterogeneity | recruiting | — | 520 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07070973 | Proactive Hemodynamic Management During Cytoreductive Surgery and HIPEC(HEMOPEC) | recruiting | N/A | 52 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07441733 | Evaluate the Implementation of Using Indocyanine Green for Sentinel Lymph Node Mapping in Breast Cancer Patients(INFLUENCE II) | recruiting | N/A | 40 | Casa di Cura Dott. PederzoliOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07532590 | Patients With Pancreatic Tumor: Use of an App to Monitor Progress in a Simple and Intuitive Way by Periodically Completing Targeted Questionnaires and Providing Educational and Informational Content (PancreasPlus). | recruiting | N/A | 185 | Casa di Cura Dott. PederzoliOTHER | 1 | May 11, 2026 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials